Biomedical research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Click here to see hierarchical division and subunit overview
Summary of publications:
Publications (original articles or review articles) published in 2019 from OUS - Section for Experimental Cancer Treatment
16 publications found
High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer
BMC Cancer, 19 (1), 488
DOI 10.1186/s12885-019-5724-z, PubMed 31122213
Immune stimulatory effect of anti-EpCAM immunotoxin - improved overall survival of metastatic colorectal cancer patients
Acta Oncol, 59 (4), 404-409
DOI 10.1080/0284186X.2019.1704864, PubMed 31876430
Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer
Cancer Immunol Immunother, 69 (3), 355-364
DOI 10.1007/s00262-019-02458-x, PubMed 31893287
Clinical relevance of pancreatobiliary and intestinal subtypes of ampullary and duodenal adenocarcinoma: Pattern of recurrence, chemotherapy, and survival after pancreatoduodenectomy
Pancreatology, 19 (2), 316-324
DOI 10.1016/j.pan.2019.01.019, PubMed 30713128
ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis
Eur J Surg Oncol, 47 (1), 134-138
DOI 10.1016/j.ejso.2019.04.014, PubMed 31036394
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy
Ann Oncol, 30 (7), 1088-1095
DOI 10.1093/annonc/mdz139, PubMed 31046124
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
Ann Oncol, 30 (7), 1154-1161
DOI 10.1093/annonc/mdz110, PubMed 30923820
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
N Engl J Med, 381 (17), 1632-1643
DOI 10.1056/NEJMoa1908075, PubMed 31566309
Combination therapies with HSP90 inhibitors against colorectal cancer
Biochim Biophys Acta Rev Cancer, 1871 (2), 240-247
DOI 10.1016/j.bbcan.2019.01.002, PubMed 30708039
Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?
Clin Transl Radiat Oncol, 21, 5-10
DOI 10.1016/j.ctro.2019.11.006, PubMed 31872084
Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer
Transl Oncol, 12 (8), 1038-1044
DOI 10.1016/j.tranon.2019.04.014, PubMed 31146167
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
Eur J Cancer, 119, 168-178
DOI 10.1016/j.ejca.2019.07.010, PubMed 31445199
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
Clin Exp Immunol, 197 (1), 74-82
DOI 10.1111/cei.13283, PubMed 30821848
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)
Eur J Cancer, 121, 144-153
DOI 10.1016/j.ejca.2019.08.014, PubMed 31581055
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial
Lancet Oncol, 20 (5), 701-710
DOI 10.1016/S1470-2045(18)30940-9, PubMed 30928620
Transplant oncology: assessment of response and tolerance to systemic chemotherapy for metastatic colorectal cancer after liver transplantation - a retrospective study
Transpl Int, 32 (11), 1144-1150
DOI 10.1111/tri.13471, PubMed 31209941